Agaimy Abbas, Laco Jan, Schubart Christoph, Stoehr Robert, Tögel Lars, Ihrler Stephan
Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany.
Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg (CCC ER-EMN), Erlangen, Germany.
Virchows Arch. 2025 Sep 6. doi: 10.1007/s00428-025-04234-y.
Benign lymphoepithelial tumors of salivary glands had been restricted to sebaceous and non-sebaceous (NSLA) lymphadenomas. However, salivary neoplasms recapitulating carcinoma showing thymus-like elements (CASTLE) have been the subject of recent case reports. We reviewed clinicopathological, immunohistochemical, and molecular findings in 20 salivary gland tumors with thymus-like phenotype (18 histologically benign and two with malignant component). Original diagnoses were NSLA (n = 11) and unclassified thymus-like lymphoepithelial neoplasms (n = 9). Patients were 13 males and 7 females aged 28 to 83 years (median, 61). All tumors originated in the parotid with a median tumor size of 2.7 cm. A cystic component was noted in eight cases (40%). Histologically, the tumors were composed of large squamoid cells with indistinct cell borders, forming large irregular branching and anastomosing aggregates within lymphoid stroma with Hassall corpuscle-like structures and intraepithelial sprinkling of lymphocytes. All tumors were diffusely positive for p63/p40 and CK5/CK14. CD5 and CD117 were expressed in 13/20 (65%) and 15/19 (79%) cases, respectively. The malignant component in two cases showed lower CD5/CD117 expression. Targeted DNA sequencing revealed pathogenic/likely pathogenic CYLD mutations in 4/7 cases (57%). One case each had a mutation in TAF1 + WISP3, DNMT3A, and BCOR. Targeted RNA sequencing revealed a YAP1::MAML2 fusion in 1/7 cases. This is the first systematic study addressing the concept of thymus-like phenotype in benign lymphoepithelial salivary gland tumors, showing that the majority of NSLAs (65%) belong to this poorly characterized category. Frequent CYLD mutations in these histologically distinct tumors represent a novel addition to the spectrum of CYLD-mutated salivary neoplasms.
涎腺良性淋巴上皮性肿瘤曾局限于皮脂腺和非皮脂腺(NSLA)腺瘤。然而,具有胸腺样成分的涎腺肿瘤(CASTLE)已成为近期病例报告的主题。我们回顾了20例具有胸腺样表型的涎腺肿瘤(18例组织学上为良性,2例有恶性成分)的临床病理、免疫组化和分子学结果。最初诊断为NSLA(n = 11)和未分类的胸腺样淋巴上皮性肿瘤(n = 9)。患者年龄28至83岁,男性13例,女性7例(中位年龄61岁)。所有肿瘤均起源于腮腺,肿瘤中位大小为2.7 cm。8例(40%)可见囊性成分。组织学上,肿瘤由细胞边界不清的大鳞状细胞组成,在淋巴样间质内形成大的不规则分支和吻合的细胞团,伴有哈氏小体样结构和上皮内淋巴细胞散在分布。所有肿瘤p63/p40和CK5/CK14均弥漫性阳性。CD5和CD117分别在13/20(65%)和15/19(79%)的病例中表达。2例恶性成分中CD5/CD117表达较低。靶向DNA测序显示4/7例(57%)存在致病/可能致病的CYLD突变。各有1例分别存在TAF1 + WISP3、DNMT3A和BCOR突变。靶向RNA测序显示1/7例存在YAP1::MAML2融合。这是第一项针对涎腺良性淋巴上皮性肿瘤中胸腺样表型概念的系统性研究,表明大多数NSLA(65%)属于这一特征不明的类别。这些组织学上不同的肿瘤中频繁出现CYLD突变,是CYLD突变的涎腺肿瘤谱中的新成员。